2476-29-1

Usage

Preparation

Preparation by hydrolysis of 4-acetamido-2-hydroxy-acetophenone with boiling aqueous hydrochloric acid at 50% HCl or at 15% HCl.

Upstream product

• 591-27-5 m-Hydroxyaniline 
• 40547-58-8 N-(4-acetyl-3-hydroxyphenyl)acetamide 
• 6317-89-1 3-acetamidophenyl acetate 
• 55792-53-5 acetic acid-(3-butoxy-anilide) 
• 536-90-3 m-Anisidine 
• 621-42-1 meta-hydroxyacetanilide 
• 588-16-9 m-methoxyacetanilide 
• 55792-62-6 acetic acid-(3-octyloxy-anilide) 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 

Downstream Products

• 207923-07-7 5-amino-2-ethyl-phenol 
• 35204-52-5 (2-hydroxy-4-mercaptophenyl)ethanone 
• 860508-06-1 3-ethyl-6-amino-2-hydroxy-benzoic acid 
• 1329166-60-0 1-[4-amino-2-(but-3-en-1-yloxy)phenyl]ethan-1-one 
• 1329166-61-1 methyl N-[4-acetyl-3-(but-3-en-1-yloxy)phenyl]carbamate 
• 107070-69-9 1-(4-(dimethylamino)-2-hydroxyphenyl)ethanone 
• 1329166-59-7 methyl N-[4-(2-bromoacetyl)-3-(but-3-en-1-yloxy)phenyl]carbamate 
• 1329166-68-8 methyl 4-(2-bromoacetyl)-3-(pent-4-enyloxy)phenylcarbamate 
• 1448349-14-1 (E)-1-(4-amino-2-hydroxyphenyl)-3-(benzo[d][1,3]dioxol-5-yl)prop-2-en-1-one 
• 1448349-07-2 (E)-1-(4-amino-2-hydroxyphenyl)-3-(4-ethylphenyl)prop-2-en-1-one 
• 1448349-05-0 (E)-1-(4-amino-2-hydroxyphenyl)-3-(4-ethoxy-3-methoxyphenyl)prop-2-en-1-one 
• 1448349-04-9 (E)-1-(4-amino-2-hydroxyphenyl )-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 1448349-03-8 (E )-1-(4-amino-2-hydroxyphenyl)-3-(3,5-bis-(trifluoromethyl)phenyl)prop-2-en-1-one 
• 1448349-02-7 (E)-1-(4-amino-2-hydroxyphenyl)-3-(4-chlorophenyl)prop-2-en-1-one 

Relevant academic research and scientific papers

Synthesis and identification of new flavonoids targeting liver X receptor β involved pathway as potential facilitators of Aβ clearance with reduced lipid accumulation

Alzheimer's disease (AD) is associated with impaired Aβ degradation in the brain. Enhancing the process of Aβ clearance is an attractive potential AD therapy. Treatment with LXR agonists may reduce Aβ levels in vivo. However, the clinical potential of man

N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof

N-sulfamoyl-N′-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions.

N-SULFAMOYL-N’-BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES

The present invention relates to novel N-sulfamoyl-N'-benzopyranpiperidines of general formula (I) and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the prophylaxis and/or treatment and/or prevention and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and its concomitant and/or secondary diseases or conditions.

Primary intermediate for oxidative coloration of hair

Primary intermediate for hair coloring compositions for oxidative dyeing of hair is 4-amino-2-(1-hydroxy-ethyl)-phenol.

Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions

Novel disubstituted bicyclic heterocycles, of which the following are exemplary: (a) 1-methyl-2-[(4-amidinophenyl)-oxymethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole, (b) 1-methyl-2-[2-(4-amidinophenyl)-ethyl]-5-[N-(N-(hydroxycarbonylmethyl)-aminocarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole, (c) 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole and (d) 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-indole. These are useful for the treatment of thrombotic disease.